MY ACCOUNT | NEWSLETTER |

Mars Vet Health invests $500M in career support programs


Veterinary health company, Mars Veterinary Health North America, has allocated $500 million in a multi-year program to increase pay and benefits, career and education opportunities, increase diversity, and relieve student debt. The company has committed to achieving these milestones by 2025. 

Specifically, the company will adopt a $15 minimum wage by the end of 2022, paid parental leave, and disability and 401k for full-time staff, institute partnerships with educational providers, and financial counseling and refinancing options for student debt. The company has also pledged to provide inclusion training, balance gender senior management teams, and collaborate with organizations such as the Diversify Veterinary Medicine Coalition and Tuskegee University College of Veterinary Medicine.

Mars includes more than 2000 veterinary centers, including Antech Diagnostics, Banfield Pet Hospital, BluePearl Specialty, and Emergency Hospitals, and VCA Animal Hospitals.  

"As a veterinarian who is deeply invested in advancing the profession – and addressing key challenges such as diversity, mental health and wellbeing, and veterinary professional shortages it is facing – we hope these commitments give Associates the support and peace of mind they need to advance their careers and provide high-quality care to pets," said Dr. Jennifer Welser, chief medical officer at Mars Veterinary Health. "But more than that, we hope our actions communicate to veterinary professionals, and especially our associates, that their voices are heard and valued as we continue to invest in programs and initiatives that are intended to impact their lives for the better directly."

Source: https://www.prnewswire.com/news-releases/mars-veterinary-health-north-america-announces-500-million-multi-year-investment-to-promote-thriving-careers-workforce-diversity-and-sustainable-change-across-the-veterinary-profession-301336869.html


Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Dr. Marjorie Bercier Publishes Study on Novel Diagnostic Approach for Prevalent Elephant Virus

Like0
Dislike0

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

Like0
Dislike0

Feline injection site sarcomas

Like0
Dislike0

C-reactive protein concentrations in canine acute pancreatitis

Like0
Dislike0

A retrospective clinical investigation of the safety and adverse effects of pantoprazole in hospitalized ruminants

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top